Molecular biology of calcific aortic valve disease: towards new pharmacological therapies

References

• Rajamannan NM, Evans FJ, Aikawa E, et al. Calcific aortic valve disease: not simply a degenerative process: a review and agenda for research from the National Heart and Lung and Blood Institute Aortic Stenosis Working Group. Executive summary: calcific aortic valve disease-2011 update. Circulation 2011;124(16):1783-91
   PubMed Web of Science ®Google Scholar
• Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997;29(3):630-4
   PubMed Web of Science ®Google Scholar
• Mathieu P, Despres JP, Pibarot P. The ’valvulo-metabolic’ risk in calcific aortic valve disease. Can J Cardiol 2007;23(Suppl B):32B-9B
   PubMedGoogle Scholar
• Bosse Y, Miqdad A, Fournier D, et al. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet 2009;2(5):489-98
   PubMedGoogle Scholar
• Olsson M, Thyberg J, Nilsson J. Presence of oxidized low density lipoprotein in nonrheumatic stenotic aortic valves. Arterioscler Thromb Vasc Biol 1999;19(5):1218-22
   PubMed Web of Science ®Google Scholar
• Cote C, Pibarot P, Despres JP, et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008;94(9):1175-80
   PubMedGoogle Scholar
• Weiss RM, Ohashi M, Miller JD, et al. Calcific aortic valve stenosis in old hypercholesterolemic mice. Circulation 2006;114(19):2065-9
   PubMed Web of Science ®Google Scholar
• Aikawa E, Aikawa M, Libby P, et al. Arterial and aortic valve calcification abolished by elastolytic cathepsin S deficiency in chronic renal disease. Circulation 2009;119(13):1785-94
   PubMedGoogle Scholar
• Teo KK, Corsi DJ, Tam JW, et al. Lipid lowering on progression of mild to moderate aortic stenosis: meta-analysis of the randomized placebo-controlled clinical trials on 2344 patients. Can J Cardiol 2011;27(6):800-8
   PubMed Web of Science ®Google Scholar
• Gerdts E, Rossebo AB, Pedersen TR, et al. Impact of baseline severity of aortic valve stenosis on effect of intensive lipid lowering therapy (from the SEAS study). Am J Cardiol 2010;106(11):1634-9
   PubMed Web of Science ®Google Scholar
• Monzack EL, Masters KS. A time course investigation of the statin paradox among valvular interstitial cell phenotypes. Am J Physiol Heart Circ Physiol 2012;303(7):H903-9
   PubMedGoogle Scholar
• Liu AC, Joag VR, Gotlieb AI. The emerging role of valve interstitial cell phenotypes in regulating heart valve pathobiology. Am J Pathol 2007;171(5):1407-18
   PubMed Web of Science ®Google Scholar
• Mathieu P, Pibarot P, Larose E, et al. Visceral obesity and the heart. Int J Biochem Cell Biol 2008;40(5):821-36
   PubMed Web of Science ®Google Scholar
• Mohty D, Pibarot P, Despres JP, et al. Association between plasma LDL particle size, valvular accumulation of oxidized LDL, and inflammation in patients with aortic stenosis. Arterioscler Thromb Vasc Biol 2008;28(1):187-93
   PubMed Web of Science ®Google Scholar
• Capoulade R, Clavel MA, Dumesnil JG, et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. J Am Coll Cardiol 2012;60(3):216-23
   PubMed Web of Science ®Google Scholar
• Mahmut A, Boulanger MC, El HD, et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 2014;63(5):460-9
   PubMed Web of Science ®Google Scholar
• Derbali H, Bosse Y, Cote N, et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 2010;176(6):2638-45
   PubMed Web of Science ®Google Scholar
• O’Brien KD, Vuletic S, McDonald TO, et al. Cell-associated and extracellular phospholipid transfer protein in human coronary atherosclerosis. Circulation 2003;108(3):270-4
   PubMed Web of Science ®Google Scholar
• Song R, Zeng Q, Ao L, et al. Biglycan induces the expression of osteogenic factors in human aortic valve interstitial cells via Toll-like receptor-2. Arterioscler Thromb Vasc Biol 2012;32(11):2711-20
   PubMedGoogle Scholar
• Osman N, Grande-Allen KJ, Ballinger ML, et al. Smad2-dependent glycosaminoglycan elongation in aortic valve interstitial cells enhances binding of LDL to proteoglycans. Cardiovasc Pathol 2013;22(2):146-55
   PubMedGoogle Scholar
• Mahmut A, Boulanger MC, Fournier D, et al. Lipoprotein lipase in aortic valve stenosis is associated with lipid retention and remodelling. Eur J Clin Invest 2013;43(6):570-8
   PubMedGoogle Scholar
• Edwards IJ, Goldberg IJ, Parks JS, et al. Lipoprotein lipase enhances the interaction of low density lipoproteins with artery-derived extracellular matrix proteoglycans. J Lipid Res 1993;34(7):1155-63
   PubMedGoogle Scholar
• Tsuzuki Y, Nguyen TK, Garud DR, et al. 4-deoxy-4-fluoro-xyloside derivatives as inhibitors of glycosaminoglycan biosynthesis. Bioorg Med Chem Lett 2010;20(24):7269-73
   PubMedGoogle Scholar
• Thanassoulis G, Campbell CY, Owens DS, et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013;368(6):503-12
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Boekholdt SM, Dube MP, et al. Lipoprotein(a) levels, genotype and incident aortic valve stenosis: a prospective mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014. [Epub ahead of print]
   PubMedGoogle Scholar
• Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014;63(5):470-7
   PubMed Web of Science ®Google Scholar
• Bouchareb R, Boulanger MC, Fournier D, et al. Mechanical strain induces the production of spheroid mineralized microparticles in the aortic valve through a RhoA/ROCK-dependent mechanism. J Mol Cell Cardiol 2014;67:49-59
   PubMed Web of Science ®Google Scholar
• Hung MY, Witztum JL, Tsimikas S. New Therapeutic Targets for Calcific Aortic Valve Stenosis: the Lipoprotein(a)-Lipoprotein-Associated Phospholipase A2-Oxidized Phospholipid Axis. J Am Coll Cardiol 2014;63(5):478-80
   PubMedGoogle Scholar
• Wilensky RL, Macphee CH. Lipoprotein-associated phospholipase A2. and atherosclerosis. Curr Opin Lipidol 2009;20(5):415-20
   PubMedGoogle Scholar
• White HD, Held C, Stewart R, et al. Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med 2014;370:1702-11
   PubMed Web of Science ®Google Scholar
• Merki E, Graham M, Taleb A, et al. Antisense oligonucleotide lowers plasma levels of apolipoprotein (a) and lipoprotein (a) in transgenic mice. J Am Coll Cardiol 2011;57(15):1611-21
   PubMed Web of Science ®Google Scholar
• McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol 2012;59(25):2344-53
   PubMed Web of Science ®Google Scholar
• Arsenault BJ, Lemieux I, Despres JP, et al. HDL particle size and the risk of coronary heart disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Atherosclerosis 2009;206(1):276-81
   PubMedGoogle Scholar
• Holmes MV, Asselbergs FW, Palmer TM, et al. Mendelian randomization of blood lipids for coronary heart disease. Eur Heart J 2014. [Epub ahead of print]
   Google Scholar
• Didonato JA, Aulak K, Huang Y, et al. Site-specific nitration of apolipoprotein A-I at tyrosine 166 is both abundant within human atherosclerotic plaque and dysfunctional. J Biol Chem 2014;289(15):10276-92
   PubMedGoogle Scholar
• Audet A, Cote N, Couture C, et al. Amyloid substance within stenotic aortic valves promotes mineralization. Histopathology 2012;61(4):610-19
   PubMedGoogle Scholar
• Arsenault BJ, Dube MP, Brodeur MR, et al. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans. Arterioscler Thromb Vasc Biol 2014;34(2):457-62
   PubMedGoogle Scholar
• Trapeaux J, Busseuil D, Shi Y, et al. Improvement of aortic valve stenosis by ApoA-I mimetic therapy is associated with decreased aortic root and valve remodelling in mice. Br J Pharmacol 2013;169(7):1587-99
   PubMedGoogle Scholar
• Busseuil D, Shi Y, Mecteau M, et al. Regression of aortic valve stenosis by ApoA-I mimetic peptide infusions in rabbits. Br J Pharmacol 2008;154(4):765-73
   PubMedGoogle Scholar
• Speidl WS, Cimmino G, Ibanez B, et al. Recombinant apolipoprotein A-I Milano rapidly reverses aortic valve stenosis and decreases leaflet inflammation in an experimental rabbit model. Eur Heart J 2010;31(16):2049-57
   PubMedGoogle Scholar
• Nagy L, Tontonoz P, Alvarez JG, et al. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 1998;93(2):229-40
   PubMed Web of Science ®Google Scholar
• Chu Y, Lund DD, Weiss RM, et al. Pioglitazone attenuates valvular calcification induced by hypercholesterolemia. Arterioscler Thromb Vasc Biol 2013;33(3):523-32
   PubMedGoogle Scholar
• Festuccia WT, Laplante M, Brule S, et al. Rosiglitazone-induced heart remodelling is associated with enhanced turnover of myofibrillar protein and mTOR activation. J Mol Cell Cardiol 2009;47(1):85-95
   PubMed Web of Science ®Google Scholar
• Nissen SE, Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 2007;356(24):2457-71
   PubMed Web of Science ®Google Scholar
• Miller JD, Chu Y, Brooks RM, et al. Dysregulation of antioxidant mechanisms contributes to increased oxidative stress in calcific aortic valvular stenosis in humans. J Am Coll Cardiol 2008;52(10):843-50
   PubMed Web of Science ®Google Scholar
• El Accaoui RN, Gould ST, Hajj GP, et al. Aortic valve sclerosis in mice deficient in endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2014;306:H1302-H13
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Subramaniam M, Stock SR, et al. Atorvastatin inhibits calcification and enhances nitric oxide synthase production in the hypercholesterolaemic aortic valve. Heart 2005;91(6):806-10
   PubMed Web of Science ®Google Scholar
• Li H, Forstermann U. Uncoupling of endothelial NO synthase in atherosclerosis and vascular disease. Curr Opin Pharmacol 2013;13(2):161-7
   PubMedGoogle Scholar
• Forstermann U, Li H. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 2011;164(2):213-23
   PubMed Web of Science ®Google Scholar
• Cote N, Mahmut A, Bosse Y, et al. Inflammation is associated with the remodeling of calcific aortic valve disease. Inflammation 2013;36(3):573-81
   PubMed Web of Science ®Google Scholar
• Yoshioka M, Yuasa S, Matsumura K, et al. Chondromodulin-I maintains cardiac valvular function by preventing angiogenesis. Nat Med 2006;12(10):1151-9
   PubMed Web of Science ®Google Scholar
• Kaden JJ, Dempfle CE, Grobholz R, et al. Inflammatory regulation of extracellular matrix remodeling in calcific aortic valve stenosis. Cardiovasc Pathol 2005;14(2):80-7
   PubMed Web of Science ®Google Scholar
• Edep ME, Shirani J, Wolf P, et al. Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 2000;9(5):281-6
   PubMed Web of Science ®Google Scholar
• Sun L, Rajamannan NM, Sucosky P. Defining the role of fluid shear stress in the expression of early signaling markers for calcific aortic valve disease. PLoS One 2013;8(12):e84433
   PubMedGoogle Scholar
• Sun L, Chandra S, Sucosky P. Ex vivo evidence for the contribution of hemodynamic shear stress abnormalities to the early pathogenesis of calcific bicuspid aortic valve disease. PLoS One 2012;7(10):e48843
   PubMedGoogle Scholar
• Charest A, Pepin A, Shetty R, et al. Distribution of SPARC during neovascularisation of degenerative aortic stenosis. Heart 2006;92(12):1844-9
   PubMed Web of Science ®Google Scholar
• Galeone A, Brunetti G, Oranger A, et al. Aortic valvular interstitial cells apoptosis and calcification are mediated by TNF-related apoptosis-inducing ligand. Int J Cardiol 2013;169(4):296-304
   PubMedGoogle Scholar
• Isoda K, Matsuki T, Kondo H, et al. Deficiency of interleukin-1 receptor antagonist induces aortic valve disease in BALB/c mice. Arterioscler Thromb Vasc Biol 2010;30(4):708-15
   PubMedGoogle Scholar
• Mahler GJ, Farrar EJ, Butcher JT. Inflammatory cytokines promote mesenchymal transformation in embryonic and adult valve endothelial cells. Arterioscler Thromb Vasc Biol 2013;33(1):121-30
   PubMed Web of Science ®Google Scholar
• El Husseini D, Boulanger MC, Mahmut A, et al. P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease. J Mol Cell Cardiol 2014;72:146-56
   PubMed Web of Science ®Google Scholar
• Tanaka T, Ogata A, Narazaki M. Tocilizumab for the treatment of rheumatoid arthritis. Expert Rev Clin Immunol 2010;6(6):843-54
   PubMed Web of Science ®Google Scholar
• Cote N, Couture C, Pibarot P, et al. Angiotensin receptor blockers are associated with a lower remodelling score of stenotic aortic valves. Eur J Clin Invest 2011;41(11):1172-9
   PubMed Web of Science ®Google Scholar
• Cote N, Pibarot P, Pepin A, et al. Oxidized low-density lipoprotein, angiotensin II and increased waist cirumference are associated with valve inflammation in prehypertensive patients with aortic stenosis. Int J Cardiol 2010;145(3):444-9
   PubMed Web of Science ®Google Scholar
• Campbell SE, Katwa LC. Angiotensin II stimulated expression of transforming growth factor-beta1 in cardiac fibroblasts and myofibroblasts. J Mol Cell Cardiol 1997;29(7):1947-58
   PubMedGoogle Scholar
• Zhang M, Wang J, Liu JH, et al. Effects of probucol on angiotensin II-induced BMP-2 expression in human umbilical vein endothelial cells. Mol Med Rep 2013;7(1):177-82
   PubMedGoogle Scholar
• O’Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med 2005;165(8):858-62
   PubMedGoogle Scholar
• Capoulade R, Clavel MA, Mathieu P, et al. Impact of hypertension and renin-angiotensin system inhibitors in aortic stenosis. Eur J Clin Invest 2013;43(12):1262-72
   PubMed Web of Science ®Google Scholar
• Cote N, Mahmut A, Fournier D, et al. Angiotensin receptor blockers are associated with reduced fibrosis and interleukin-6 expression in calcific aortic valve disease. Pathobiology 2014;81(1):15-24
   PubMedGoogle Scholar
• Fujisaka T, Hoshiga M, Hotchi J, et al. Angiotensin II promotes aortic valve thickening independent of elevated blood pressure in apolipoprotein-E deficient mice. Atherosclerosis 2013;226(1):82-7
   PubMed Web of Science ®Google Scholar
• Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol 2004;44(9):1859-66
   PubMed Web of Science ®Google Scholar
• Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption of the aortic valve in hypercholesterolemic rabbits. J Am Coll Cardiol 2007;49(13):1482-9
   PubMedGoogle Scholar
• O’Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med 2004;52(3):185-91
   PubMedGoogle Scholar
• Garg V, Muth AN, Ransom JF, et al. Mutations in NOTCH1 cause aortic valve disease. Nature 2005;437(7056):270-4
   PubMed Web of Science ®Google Scholar
• Guruharsha KG, Kankel MW, Artavanis-Tsakonas S. The Notch signalling system: recent insights into the complexity of a conserved pathway. Nat Rev Genet 2012;13(9):654-66
   PubMed Web of Science ®Google Scholar
• Nigam V, Srivastava D. Notch1 represses osteogenic pathways in aortic valve cells. J Mol Cell Cardiol 2009;47(6):828-34
   PubMed Web of Science ®Google Scholar
• Nus M, MacGrogan D, Martinez-Poveda B, et al. Diet-induced aortic valve disease in mice haploinsufficient for the Notch pathway effector RBPJK/CSL. Arterioscler Thromb Vasc Biol 2011;31(7):1580-8
   PubMedGoogle Scholar
• Ducharme V, Guauque-Olarte S, Gaudreault N, et al. NOTCH1 genetic variants in patients with tricuspid calcific aortic valve stenosis. J Heart Valve Dis 2013;22(2):142-9
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Subramaniam M, Rickard D, et al. Human aortic valve calcification is associated with an osteoblast phenotype. Circulation 2003;107(17):2181-4
   PubMed Web of Science ®Google Scholar
• Rajamannan NM, Subramaniam M, Caira F, et al. Atorvastatin inhibits hypercholesterolemia-induced calcification in the aortic valves via the Lrp5 receptor pathway. Circulation 2005;112(9 Suppl):I229-34
   PubMedGoogle Scholar
• Komiya Y, Habas R. Wnt signal transduction pathways. Organogenesis 2008;4(2):68-75
   PubMedGoogle Scholar
• Caira FC, Stock SR, Gleason TG, et al. Human degenerative valve disease is associated with up-regulation of low-density lipoprotein receptor-related protein 5 receptor-mediated bone formation. J Am Coll Cardiol 2006;47(8):1707-12
   PubMed Web of Science ®Google Scholar
• Zhang R, Oyajobi BO, Harris SE, et al. Wnt/beta-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts. Bone 2013;52(1):145-56
   PubMed Web of Science ®Google Scholar
• Rajamannan NM. The role of Lrp5/6 in cardiac valve disease: experimental hypercholesterolemia in the ApoE-/-/Lrp5-/- mice. J Cell Biochem 2011;112(10):2987-91
   PubMedGoogle Scholar
• Deregowski V, Gazzerro E, Priest L, et al. Notch 1 overexpression inhibits osteoblastogenesis by suppressing Wnt/beta-catenin but not bone morphogenetic protein signaling. J Biol Chem 2006;281(10):6203-10
   PubMedGoogle Scholar
• Zhang M, Liu X, Zhang X, et al. MicroRNA-30b is a multifunctional regulator of aortic valve interstitial cells. J Thorac Cardiovasc Surg 2014;147(3):1073-80
   PubMed Web of Science ®Google Scholar
• Yanagawa B, Lovren F, Pan Y, et al. miRNA-141 is a novel regulator of BMP-2-mediated calcification in aortic stenosis. J Thorac Cardiovasc Surg 2012;144(1):256-62
   PubMedGoogle Scholar
• Hupkes M, Sotoca AM, Hendriks JM, et al. MicroRNA miR-378 promotes BMP2-induced osteogenic differentiation of mesenchymal progenitor cells. BMC Mol Biol 2014;15:1-15
   PubMed Web of Science ®Google Scholar
• Jian B, Narula N, Li QY, et al. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg 2003;75(2):457-65
   PubMed Web of Science ®Google Scholar
• Ankeny RF, Thourani VH, Weiss D, et al. Preferential activation of SMAD1/5/8 on the fibrosa endothelium in calcified human aortic valves-association with low BMP antagonists and SMAD6. PLoS One 2011;6(6):e20969
   PubMedGoogle Scholar
• Hutcheson JD, Chen J, Sewell-Loftin MK, et al. Cadherin-11 regulates cell-cell tension necessary for calcific nodule formation by valvular myofibroblasts. Arterioscler Thromb Vasc Biol 2013;33(1):114-20
   PubMedGoogle Scholar
• Chen JH, Chen WL, Sider KL, et al. beta-catenin mediates mechanically regulated, transforming growth factor-beta1-induced myofibroblast differentiation of aortic valve interstitial cells. Arterioscler Thromb Vasc Biol 2011;31(3):590-7
   PubMed Web of Science ®Google Scholar
• Hutcheson JD, Ryzhova LM, Setola V, et al. 5-HT(2B) antagonism arrests non-canonical TGF-beta1-induced valvular myofibroblast differentiation. J Mol Cell Cardiol 2012;53(5):707-14
   PubMed Web of Science ®Google Scholar
• Lau WL, Pai A, Moe SM, Giachelli CM. Direct effects of phosphate on vascular cell function. Adv Chronic Kidney Dis 2011;18(2):105-12
   PubMedGoogle Scholar
• Linefsky JP, O’Brien KD, Sachs M, et al. Serum phosphate is associated with aortic valve calcification in the Multi-ethnic Study of Atherosclerosis (MESA). Atherosclerosis 2014;233(2):331-7
   PubMedGoogle Scholar
• Mathieu P. Pharmacology of ectonucleotidases: relevance for the treatment of cardiovascular disorders. Eur J Pharmacol 2012;696(1-3):1-4
   PubMedGoogle Scholar
• Mathieu P, Voisine P, Pepin A, et al. Calcification of human valve interstitial cells is dependent on alkaline phosphatase activity. J Heart Valve Dis 2005;14(3):353-7
   PubMedGoogle Scholar
• Cote N, El HD, Pepin A, et al. ATP acts as a survival signal and prevents the mineralization of aortic valve. J Mol Cell Cardiol 2012;52(5):1191-202
   PubMedGoogle Scholar
• Okawa A, Nakamura I, Goto S, et al. Mutation in Npps in a mouse model of ossification of the posterior longitudinal ligament of the spine. Nat Genet 1998;19(3):271-3
   PubMedGoogle Scholar
• El Husseini D, Boulanger MC, Fournier D, et al. High expression of the Pi-transporter SLC20A1/Pit1 in calcific aortic valve disease promotes mineralization through regulation of Akt-1. PLoS One 2013;8(1):e53393
   PubMed Web of Science ®Google Scholar
• Cote N, El Husseini D, Pepin A, et al. Inhibition of ectonucleotidase with ARL67156 prevents the development of calcific aortic valve disease in warfarin-treated rats. Eur J Pharmacol 2012;689(1-3):139-46
   PubMedGoogle Scholar